U
Uwe Haberkorn
Researcher at University Hospital Heidelberg
Publications - 127
Citations - 8605
Uwe Haberkorn is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Prostate cancer & PET-CT. The author has an hindex of 40, co-authored 127 publications receiving 5930 citations. Previous affiliations of Uwe Haberkorn include German Cancer Research Center & Heidelberg University.
Papers
More filters
Journal ArticleDOI
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Clemens Kratochwil,Frank Bruchertseifer,Frederik L. Giesel,Mirjam Weis,Frederik A. Verburg,Felix M. Mottaghy,Klaus Kopka,Christos Apostolidis,Uwe Haberkorn,Alfred Morgenstern +9 more
TL;DR: Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.
Journal ArticleDOI
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.
Wolfgang P. Fendler,Wolfgang P. Fendler,Matthias Eiber,Matthias Eiber,Mohsen Beheshti,Jamshed Bomanji,Francesco Ceci,Steven Cho,Frederik L. Giesel,Uwe Haberkorn,Thomas A. Hope,Klaus Kopka,Bernd J. Krause,Felix M. Mottaghy,Heiko Schöder,John Sunderland,Simon Wan,Hans-Juergen Wester,Stefano Fanti,Ken Herrmann +19 more
TL;DR: These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer imaging and are needed for implementation of this modality in science and routine clinical practice.
Journal ArticleDOI
Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours
I. Buchmann,M. Henze,S. Engelbrecht,Michael Eisenhut,A. Runz,Martin Schäfer,Tobias Schilling,Sabine Haufe,T. Herrmann,Uwe Haberkorn +9 more
TL;DR: 68Ga-DOTATOC PET is superior to 111In-DTPAOC SPECT in the detection of NET manifestations in the lung and skeleton and similar for the detection in the liver and brain and is advantageous in guiding the clinical management.
Journal ArticleDOI
Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein
Thomas Lindner,Anastasia Loktev,Anastasia Loktev,Anastasia Loktev,Annette Altmann,Annette Altmann,Frederik L. Giesel,Clemens Kratochwil,Jürgen Debus,Jürgen Debus,Dirk Jäger,Walter Mier,Uwe Haberkorn +12 more
TL;DR: FAPI-04 represents a promising tracer for both diagnostic imaging and, possibly, targeted therapy of malignant tumors with a high content of activated fibroblasts, such as breast cancer.
Journal ArticleDOI
68Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers.
Frederik L. Giesel,Clemens Kratochwil,Thomas Lindner,Manfred M. Marschalek,Anastasia Loktev,Wencke Lehnert,Jürgen Debus,Jürgen Debus,Dirk Jäger,Paul Flechsig,Annette Altmann,Walter Mier,Uwe Haberkorn +12 more
TL;DR: FAPI PET/CT is a new diagnostic method in imaging cancer patients in contrast to 18F-FDG, no diet or fasting in preparation for the examination is necessary, and image acquisition can potentially be started a few minutes after tracer application.